Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma  Steven F. Weinstein, MD, Rohit Katial, MD, Shyamalie Jayawardena,

Published byVille-Veikko Oksanen Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma  Steven F. Weinstein, MD, Rohit Katial, MD, Shyamalie Jayawardena,"— Presentation transcript:

1 Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma 
Steven F. Weinstein, MD, Rohit Katial, MD, Shyamalie Jayawardena, PhD, Gianluca Pirozzi, MD, Heribert Staudinger, MD, Laurent Eckert, PhD, Vijay N. Joish, PhD, Nikhil Amin, MD, Jaman Maroni, MD, Paul Rowe, MD, Neil M.H. Graham, MD, Ariel Teper, MD  Journal of Allergy and Clinical Immunology  Volume 142, Issue 1, Pages e1 (July 2018) DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions

2 Fig 1 CONSORT diagram. Intention-to-treat patients from study NCT who received dupilumab 200 or 300 mg q2w or placebo by PAR/non-PAR status (patients receiving dupilumab 200 or 300 mg q4w [shaded] are not reported). CONSORT, Consolidated Standards of Reporting Trials; q4w, every 4 weeks; Pts, patients. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

3 Fig 2 LS mean difference and 95% CI for SNOT-22 total score and PAR-associated individual items at week 24 in asthma patients with or without PAR for dupilumab 200 mg q2w vs placebo (A) and dupilumab 300 mg q2w vs placebo (B). Negative values are indicative of better improvement for nasal symptoms. LS, Least squares. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

Download ppt "Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma  Steven F. Weinstein, MD, Rohit Katial, MD, Shyamalie Jayawardena,"

Similar presentations

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Children with allergic and nonallergic rhinitis have a similar risk of asthma  Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Children with allergic and nonallergic rhinitis have a similar risk of asthma  Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Similar presentations

Ads by Google